Business / Finance

RSS

Orexo reports net revenues of MSEK 55.2 for second quarter 2011

OREXO: STRONG SALES INCREASE FOR ABSTRAL. For the period. Royalty revenues from Abstral sales in Europe rose to MSEK 30.4.

10 Aug 2011

In bid to calm markets, Obama urges deficit reduction approach that includes 'modest adjustments' to Medicare

As the stock market plunged, President Barack Obama said the nation's deficit couldn't be ignored. He recommended an approach that includes spending cuts as well as increased tax revenue and "modest adjustments" to health care programs. Meanwhile, health care stocks were among those that posted double-digit losses, and, as the fallout from S & P's downgrade continues, some states are at more risk than others.

10 Aug 2011

Enobia raises US$40M through private placement

Enobia Pharma Inc., a clinical stage biotech company focused on developing novel therapeutics for serious bone disorders, today announced that it has raised US$40 million through the private placement of approximately 13,724,000 shares of its common stock to new pharmaceutical and financial investors.

10 Aug 2011

New report: U.S. antiseptics and disinfectants market to reach $2.9B by 2016

In 2009, the disinfectant and antiseptic market was worth around $3.4 billion, but by 2010 had grown over 12%, to reach a value of $3.8 billion, according to a new report available from companiesandmarkets.com.

9 Aug 2011

Akela announces new corporate focus on PharmaForm

Akela Pharma, Inc. today announced a new strategic focus on its profitable pharmaceutical contract manufacturing business, PharmaForm, LLC.

9 Aug 2011

CIGNA launches new office and operations in Turkey

CIGNA, a leader in direct marketed supplemental health, life and accident insurance in the international marketplace, today announced the launch of a new office and operations in Turkey.

9 Aug 2011

Pharmasset declares two-for-one split of common stock

Pharmasset, Inc. announces that its Board of Directors declared a two-for-one split of Pharmasset's common stock, par value $0.001 per share, in the form of a 100% common stock dividend.

9 Aug 2011

TSO3 second quarter revenues increase to $703,000

TSO3 Inc. an innovator in sterilization technology for medical devices in healthcare settings, posted its highest quarterly revenues in its second quarter of 2011.

9 Aug 2011

Simcere second quarter total revenue increases 0.3% to US$84.4 million

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported preliminary unaudited financial results for the quarter ended June 30, 2011.

9 Aug 2011

GTx reports revenue of $1.6 million for second quarter 2011

GTx, Inc. today reported financial results for the second quarter of 2011. The net loss for the quarter ended June 30, 2011 was $10.7 million compared with a net loss of $12.9 million for the quarter ended June 30, 2010.

9 Aug 2011

Medidata Solutions second quarter net revenues increase 25% to $50.2 million

Medidata Solutions, a leading global provider of SaaS-based clinical technology solutions that enhance the efficiency of clinical development, today announced its financial results for the second quarter 2011, as well as provided financial guidance for the third quarter and full year 2011.

9 Aug 2011

PHT total revenues increase 10% for first half of 2011

PHT Corporation completed its most successful Q2 in company history on June 30, 2011. The strong, outstanding results reflect the growing worldwide adoption of its market-leading ePRO Systems.

9 Aug 2011

Gilead to acquire Genentech's OCP facility, other process development assets

Gilead Sciences, Inc. today announced that the company has signed a definitive agreement under which Gilead will purchase a clinical biologics manufacturing facility and certain process development assets located in Oceanside, California from Genentech, a member of the Roche Group.

9 Aug 2011

K-V sells assets of Nesher to Zydus and Zynesher Pharmaceuticals

K-V Pharmaceutical Company today announced the completion and closing of the previously announced sale of assets of Nesher Pharmaceuticals, Inc., the Company's wholly-owned generic subsidiary, and the Company's generic business and assets to Zydus Pharmaceuticals (USA), Inc and Zynesher Pharmaceuticals (USA) LLC.

9 Aug 2011

Lexicon's second quarter revenues decrease 55% to $0.6 million

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and six months ended June 30, 2011.

9 Aug 2011

HUYA enters strategic partnership with King's Lab

HUYA Bioscience International, a leader in globalizing China's biopharmaceutical innovations, today announced a strategic partnership with the Shanghai Jiao Tong University School of Pharmacy King's Lab. The alliance with HUYA will assist King's Lab in accelerating the development of their novel drugs to international standards.

8 Aug 2011

A.P. Pharma second quarter net loss decreases to $1.9 million

A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2011 and highlighted its recent corporate progress.

8 Aug 2011

Symphony announces acquisition of JGI

Symphony Corporation, a global healthcare technology solutions provider, today announced the acquisition of JGI, a New Jersey-based Human Capital Management consulting and technology firm with a significant presence in the healthcare industry nationally.

8 Aug 2011

Response Genetics second quarter total revenue increases 18.8% to $6.7 million

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results and business progress for the second quarter ended June 30, 2011.

8 Aug 2011

Kaan Medikal to distribute Saladax's My5-FU diagnostic test in Turkey

Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Kaan Medikal will serve as the exclusive distributor of Saladax's My5-FU diagnostic test throughout the Turkish market.

8 Aug 2011